United Therapeutics Corporation (UTHR) CEO Sells $160,026.95 in Stock
United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,241 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $128.95, for a total transaction of $160,026.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of United Therapeutics Corporation (NASDAQ UTHR) traded up $3.33 during mid-day trading on Friday, reaching $133.32. 342,729 shares of the company traded hands, compared to its average volume of 558,225. United Therapeutics Corporation has a 52 week low of $112.01 and a 52 week high of $169.89. The stock has a market capitalization of $5,760.00, a PE ratio of 10.98 and a beta of 1.38.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The company had revenue of $445.50 million for the quarter, compared to analysts’ expectations of $426.43 million. During the same quarter last year, the company posted $4.23 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. equities research analysts expect that United Therapeutics Corporation will post 12.29 EPS for the current fiscal year.
UTHR has been the topic of a number of recent analyst reports. ValuEngine cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 8th. Zacks Investment Research upgraded shares of United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Oppenheimer restated a “buy” rating on shares of United Therapeutics in a report on Friday, September 8th. Cowen restated a “hold” rating and issued a $129.00 target price on shares of United Therapeutics in a report on Friday, October 27th. Finally, HC Wainwright restated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a report on Thursday, October 26th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. United Therapeutics presently has a consensus rating of “Hold” and an average price target of $136.10.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.